MG
TCRR

Michael Gelband’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Michael Gelband’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-37,024
Closed -$173K – 2805
2021
Q4 		$173K Sell
37,024
-28,384
-43% -$177K ﹤0.01% 1857
2021
Q3 		$557K Buy
65,408
+54,122
+480% +$765K 0.01% 1318
2021
Q2 		$185K Buy
+11,286
New +$228K ﹤0.01% 2012

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Michael Gelband's TCRR Position: Q1 2022 in Review

Michael Gelband sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 37,024 shares — an estimated $173K sold.

Michael Gelband first reported a position in TCRR in Q2 2021 and held it in 3 quarters. The position peaked at $557K in Q3 2021. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Michael Gelband reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 37,024 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $173K.
  • Michael Gelband first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Michael Gelband's TCR2 Therapeutics Inc. Common Stock position peaked at $557K in Q3 2021.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.